Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.

Abstract

Clinically amelanotic lentigo maligna often resembles an inflammatory lesion rather than a melanoma in situ. We present two cases of extensive amelanotic lentigo maligna presenting as gradually enlarging erythematous patches on the faces of women following incomplete excisions of lentigo maligna. Because of their site and size, therapeutic options were limited; the lesions have, however, resolved (clinically and histologically) following the topical application of 5% imiquimod cream. We discuss the rationale for the use of imiquimod in the treatment of lentigo maligna.

• Authors: Ann-Marie Powell, Robin Russell-Jones
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 50 Issue 5 Pg. 792-6 (May 2004) ISSN: 0190-9622 [Print] United States
• PMID: 15097969 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Aminoquinolines
• Ointments
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage)
• Administration, Topical
• Aged
• Aminoquinolines (administration & dosage)
• Female
• Humans
• Hutchinson's Melanotic Freckle (drug therapy, pathology, surgery)
• Imiquimod
• Middle Aged
• Ointments
• Skin Neoplasms (drug therapy, pathology, surgery)